Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results and Corporate Update
Conference Call & Webcast Details | |
Date: | |
Time: | |
Toll Free: | (844) 348-3801 |
International: | (213) 358-0955 |
Conference ID: | 9992536 |
Webcast: | https://edge.media-server.com/mmc/p/b5td2coz |
A live webcast of the conference call can be accessed in the Investors section of Editas Medicine website at https://www.editasmedicine.com/.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts:
Investors
(617) 401-9083
mark.mullikin@editasmed.com
Media
(617) 401-0113
cristi.barnett@editasmed.com
Source: Editas Medicine, Inc.